Skip to main content
. Author manuscript; available in PMC: 2023 Jan 20.
Published in final edited form as: Cancer Res Commun. 2022 Jun 6;2(6):402–416. doi: 10.1158/2767-9764.CRC-22-0124

Figure 1. SMOi-induced mutations to SHH pathway genes only occur in MBs in which CSCs depend on the SHH signaling.

Figure 1.

A) A schematic of the major hypothesis tested in the study. B) Gross images of vehicle and LDE225-treated fSmoM2;hGFAP-cre brains at harvest. C) Kaplan-Meier survival curve analysis showing no significant survival benefit of LDE225 treatment. D) GLI1 protein level is reduced in LDE-treated fSmoM2;GFAPcre tumors in vivo. E) A summary of high impact mutations in vehicle and LDE225 treated fSmoM2;hGFAP-cre MBs. F) A summary of identified mutations and copy number alterations in SHH pathway genes in SMOi-resistant SI-CSC and SD-CSC Ptch;p53 MB. G) LDE225-induced SMO mutation in Ptch;p53 SD-CSC tumor. H) LDE225-induced Gli2 amplification observed in two SD-CSC tumors from the same cohort, which is not observed in any SI-CSC MBs. CNV compared to Vehicle treated tumor from the same cohort.